INNOCAN PHARMA Corp

corporate_fare Company Profile

INNOCAN PHARMA Corp

INNPF·OTC·Life Sciences·CIK 0001889791

InnoCan Pharma Corporation is a pharmaceutical technology company operating in the United States, Canada, Europe, and internationally. The company has two business segments: Online sales and Other Operations. InnoCan Pharma is developing a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is currently in the preclinical trial phase. This platform is being developed to treat chronic pain management in both human and veterinary health sectors. The company also provides a pain-relieving topical composition, along with compositions designed for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. Additionally, InnoCan Pharma Corporation is involved in the development, manufacture, and marketing of cosmetic products. The company was founded in 2017 and is headquartered in Calgary, Canada.

INNOCAN PHARMA Corp (OTC:INNPF) is a publicly traded company in the Life Sciences sector. Wiseek monitors INNPF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Innocan Pharma Reports Q1 Revenue Up 29.7% Sequentially, Defers US IPO (2026-05-27)
INNOCAN PHARMA Files F-1/A for Highly Dilutive IPO to Fund Pre-Clinical CBD Drug Development Amidst Going Concern Warning (2026-04-03)
Innocan Pharma Reports 9.6% Revenue Decline to $26.6M in 2025, Eyes U.S. Public Offering (2026-03-31)
INNOCAN PHARMA Files F-1 for Highly Dilutive Unit Offering to Fund CBD Drug Development Amidst Going Concern (2026-03-16)

Insider Transactions

INNPF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with I →

show_chartPrice Chart

Loading chart...

feed INNPF - Latest Insights

Filing Type

Date Range

INNPF

May 27, 2026, 4:00 PM EDT

Source: PR Newswire

Importance Score:

Innocan Pharma Reports Q1 Revenue Up 29.7% Sequentially, Defers US IPO

Price at Filing: $2.50

Real-time Price: $2.40

Change: -$0.100 (-4%)

Market Cap: $10.797M

Sentiment: Neutral

View Wiseek Article

INNPF

Apr 03, 2026, 4:30 PM EDT

Filing Type: F-1/A

Importance Score:

INNOCAN PHARMA Files F-1/A for Highly Dilutive IPO to Fund Pre-Clinical CBD Drug Development Amidst Going Concern Warning

Price at Filing: $4.95

Real-time Price: $2.40

Change: -$2.55 (-52%)

Market Cap: $10.797M

Sentiment: Negative

View Wiseek Article

INNPF

Mar 31, 2026, 3:00 AM EDT

Source: Dow Jones Newswires

Importance Score:

Innocan Pharma Reports 9.6% Revenue Decline to $26.6M in 2025, Eyes U.S. Public Offering

Price at Filing: $4.95

Real-time Price: $2.40

Change: -$2.55 (-52%)

Market Cap: $10.797M

Sentiment: Neutral

View Wiseek Article

INNPF

Mar 16, 2026, 4:01 PM EDT

Filing Type: F-1

Importance Score:

INNOCAN PHARMA Files F-1 for Highly Dilutive Unit Offering to Fund CBD Drug Development Amidst Going Concern

Price at Filing: $5.07

Real-time Price: $2.40

Change: -$2.67 (-53%)

Market Cap: $10.797M

Sentiment: Neutral

View Wiseek Article

corporate_fare Company Profile